公开(公告)号：US11091441B2

公开(公告)日：2021-08-17

申请号：US17069386

申请日：2020-10-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert Bichler ,  Jean-Jacques Alexandre Cadieux ,  Matthew David Tandy ,  Gregory N. Beatch

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US20210171537A1

公开(公告)日：2021-06-10

申请号：US16805895

申请日：2020-03-02

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  David Earl Bogucki ,  Kristen Nicole Burford ,  Sultan Chowdhury ,  Charles Jay Cohen ,  Shannon Marie Decker ,  Christoph Martin Dehnhardt ,  Robert Joseph Devita ,  James Roy Empfield ,  Thilo Focken ,  Michael Edward Grimwood ,  Syed Abid Hasan ,  Qi Jia ,  James Philip Johnson, JR. ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D491/107 ,  C07D493/10 ,  C07D237/20 ,  C07D213/76 ,  C07D239/69 ,  C07D261/16 ,  C07D263/50 ,  C07D275/03 ,  C07D277/52 ,  C07D285/08 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D417/12 ,  C07D487/10 ,  C07D417/14 ,  C07D451/06

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20210155588A1

公开(公告)日：2021-05-27

申请号：US17011355

申请日：2020-09-03

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Sultan CHOWDHURY ,  Christoph Martin DEHNHARDT ,  Thilo FOCKEN ,  Michael Edward GRIMWOOD ,  Ivan William HEMEON ,  Steven MCKERRALL ,  Daniel SUTHERLIN

IPC: C07C381/10 ,  C07D401/12 ,  C07D205/04 ,  C07D211/22 ,  C07D211/42 ,  C07D213/69 ,  A61P25/04

Abstract: The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20210147363A1

公开(公告)日：2021-05-20

申请号：US17069386

申请日：2020-10-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Paul Robert BICHLER ,  Jean-Jacques Alexandre CADIEUX ,  Matthew David TANDY ,  Gregory N. BEATCH

IPC: C07D217/04

Abstract: The present disclosure provides solid state forms of a selective potassium channel modulator and pharmaceutical compositions comprising the solid state crystalline forms and pharmaceutically acceptable excipients, and methods for preparing and using the solid state forms and the pharmaceutical compositions thereof.

公开(公告)号：US10899732B2

公开(公告)日：2021-01-26

申请号：US15779065

申请日：2016-11-22

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Chien-an Chen ,  Sultan Chowdhury ,  Shannon Marie Decker ,  Christoph Martin Dehnhardt ,  Ivan William Hemeon ,  Steven McKerrall ,  Brian Salvatore Safina ,  Tao Sheng ,  Dan Sutherlin

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D231/56 ,  C07D403/04 ,  C07D405/04 ,  C07D403/06 ,  C07D403/12 ,  A61P29/00

Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20190382398A1

公开(公告)日：2019-12-19

申请号：US16440459

申请日：2019-06-13

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Kristen Nicole Burford ,  Thilo Focken ,  Verner Alexander Lofstrand ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D417/12 ,  C07D277/52 ,  C07D413/12 ,  A61P25/08

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

公开(公告)号：US20190071449A1

公开(公告)日：2019-03-07

申请号：US16156718

申请日：2018-10-10

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Ronen Ben-David ,  Stephen Bierlmaier ,  Ralph Curtis Haltiwanger ,  Alexandr Jegorov ,  Raeann Ruiyun Wu ,  Mehran Yazdanian

IPC: C07D491/20 ,  A61K31/407

CPC classification number: C07D491/20 ,  A61K31/407 ,  C07B2200/13 ,  H05K999/99

Abstract: The present invention provides solid state forms of certain spiro-oxindole compounds, such as funapide and the racemic mixture of funapide and its corresponding (R) enantiomer, pharmaceutical compositions comprising the solid state forms and processes for preparing the solid state forms and the pharmaceutical compositions.

公开(公告)号：US20180346441A1

公开(公告)日：2018-12-06

申请号：US15779065

申请日：2016-11-22

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Chien-an CHEN ,  Sultan CHOWDHURY ,  Shannon Marie DECKER ,  Christoph Martin DEHNHARDT ,  Ivan William HEMEON ,  Steven MCKERRALL ,  Brian SAFINA ,  Tao SHENG ,  Dan SUTHERLIN

IPC: C07D401/04 ,  C07D403/04 ,  C07D401/14 ,  C07D231/56 ,  C07D405/14 ,  C07D405/04 ,  A61P29/00

CPC classification number: C07D401/04 ,  A61P29/00 ,  C07D231/56 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/04 ,  C07D405/14

Abstract: The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, n, ring A, X2, L, m, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10125098B2

公开(公告)日：2018-11-13

申请号：US15988956

申请日：2018-05-24

Applicant: GENENTECH, INC. ,  XENON PHARMACEUTICALS INC.

Inventor： Jean-Christophe Andrez ,  Philippe Bergeron ,  Paul Robert Bichler ,  Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Wei Gong ,  Michael Edward Grimwood ,  Abid Hasan ,  Ivan William Hemeon ,  Qi Jia ,  Brian Safina ,  Shaoyi Sun ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D207/16 ,  C07D277/06 ,  C07D413/14 ,  C07D413/12 ,  C07D401/10 ,  C07D401/12 ,  C07C235/54 ,  C07D405/10 ,  C07D403/14 ,  C07D471/08

Abstract: The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US10118932B2

公开(公告)日：2018-11-06

申请号：US15625724

申请日：2017-06-16

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Ronen Ben-David ,  Stephen Bierlmaier ,  Ralph Curtis Haltiwanger ,  Alexandr Jegorov ,  Raeann Ruiyun Wu ,  Mehran Yazdanian

IPC: C07D491/20 ,  A61K31/407

Abstract: The present invention provides solid state forms of certain spiro-oxindole compounds, such as funapide and the racemic mixture of funapide and its corresponding (R) enantiomer, pharmaceutical compositions comprising the solid state forms and processes for preparing the solid state forms and the pharmaceutical compositions.